Hudson face mask, and blood pressure, ECG, and oxygen saturation were monitored throughout. At the commencement of surgery the patient felt nauseated and metoclopramide 10 mg was given IV. Following delivery of the baby 5 units Syntocinon was given IV and this produced a minimal fall of systolic blood pressure (SBP) from 110 mmHg to 100 mmHg. Bleeding from the broad ligament required the uterus to be exteriorised to attain haemostasis. During manipulation of the uterus the patient developed chest pain which settled without treatment. Following return of the uterus to the abdomen the SBP fell to 90 mmHg and the patient vomited twice. The SBP returned to 100 mmHg following a fluid load of 500 ml lactated Ringers solution.
Throughout the procedure the patient's heart rate was between 95-105 bpm, and oxygen saturation 98070. At the end of surgery fentanyl 100 ftg (in 10 ml with normal saline) was given epidurally.
She was transferred to the recovery room. Her SBP on arrival was 90 mmHg. During the subsequent hour she developed severe hypotension (SBP below 60 mmHg). She became distressed and developed intense jaw pain. Intravenous resuscitation included 2000 ml crystalloid, 1000 ml Haemaccel, ephedrine 6 mg, and adrenaline 2 mg (20 ml x 1:10,000), followed by an adrenaline infusion. During resuscitation it was noted that she was developing facial and generalised oedema.
An emergency laparotomy was performed because of suspected major intra-abdominal bleeding. Preoxygenation and cricoid pressure were performed and anaesthesia was induced with ketamine, thiopentone, and succinylcholine. Endotracheal intubation proved extremely difficult due to gross laryngeal oedema, and laparotomy revealed oedematous tissues but no bleeding.
Postoperatively the patient was transferred to the Intensive Care Unit of another hospital. She required ventilatory and circulatory support for fourteen hours and had pulmonary oedema for five days. She eventually made a full recovery.
INVESTIGATION
The differential diagnosis included drug-induced anaphylaxis, and Adult Respiratory Distress Syndrome secondary to aspiration. Six weeks later intradermal (ID) skin testing was performed using a modification of the Fisher protocol. 3 The drugs tested were lignocaine, bupivacaine, fentanyl, metoclopramide and Syntocinon. The result to Syntocinon was equivocal, but all the other drugs were negative. Because Syntocinon is not a drug used normally for ID skin testing it was decided to perform a control test on 18 informed volunteers. Using 0.02 ml Syntocinon 1:1000 injected ID, nine out of the 18 had a similar equivocal response to the patient's, namely, intense discomfort on injection and at 15 minutes a blanched wheal and no flare.
Because both the patient and her husband wanted advice concerning the possible risks with a future pregnancy, after detailed discussion it was decided to proceed with direct challenges.
On different days informed consent was obtained and uneventful direct IV challenges were performed with lignocaine, bupivacaine, metoclopramide and fentanyl. However, when performing serial dilution IV challenges with Syntocinon, the patient started to develop symptoms. Thirty minutes after 1.0 ml Syntocinon 1:200 she experienced the same jaw pain she had had after the LUSCS.
She then felt her throat was "tight", and on auscultation she had mild bilateral wheeze. Her pulse increased from 90 bpm to 110 bpm. She was given diphenhydramine 50 mg IV, nebulised adrenaline and a low-dose adrenaline infusion. Within twenty minutes her symptoms and signs had completely resolved.
Syntocinon contains the active ingredient oxytocin, and the inactive ingredients sodium acetate, chlorbutol (chlorbutanol), ethanol and acetic acid. It was felt unlikely that the patient would be allergic to the oxytocin, as it is identical in structure to the human nonapeptide. Chlorbutol is known to be allergenic, and is present in a number of preparations. It was therefore decided to perform direct IV challenges with chlorbutol. Informed consent was obtained and within five minutes of 1 ml 1:1000 chlorbutol, she developed the same jaw pain. An adrenaline infusion was commenced immediately and IV promethazine 25 mg was given. Within ten minutes the jaw pain had resolved and no further symptoms developed.
DISCUSSION
Only two previous reports of anaphylactoid reactions to Syntocinon could be found in the literature. " The first of these was not conclusive. One death has been attributed to Syntocinon anaphylaxis in 1970 in India but no detailed information of the case is available. 6 (P. Krupp, Sandoz, Basle, Switzerland 1991. Personal communication.) Clearly these are rare events, and the delayed onset in this case contributed to the delay in treatment and diagnosis. Like many women of childbearing age, the patient had had a general anaesthetic for removal of retained products of conception in the recent past, when Syntocinon had been given uneventfully. Following the 5 units Syntocinon IV injection during the LUSCS there was a transient small fall in SBP which was regarded as a common cardiovascular effect of the IV bolus. ".-Drug-induced anaphylaxis was considered a likely diagnosis because of the combination of severe hypotension and facial and generalised oedema. Unfortunately ID skin testing was not helpful, and because the patient wanted to have more children, she was prepared to have IV challenges, even though the risks were carefully explained. Obviously this form of testing should only be undertaken after due deliberation, with all suitable monitoring and resuscitation equipment available.
The symptoms elicited with intravenous challenges of diluted Syntocinon and chlorbutol were conclusive and readily treated. Information has since been obtained from all the drug companies in New Zealand and the patient now carries a list of all preparations available in New Zealand that contain chlorbutol.
Of importance is the fact that the content of preparations vary in different countries, and indeed adrenaline may contain chlorbutol.
It must be remembered that when an anaphylactoid reaction occurs, it may be an inactive ingredient in a preparation that may be the trigger, 8 and it is important that this is identified, both for the sake of the patient and to improve the safety of the agents we use.
